|Articles|April 1, 1998

Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
Volume 4
Issue 4 Suppl

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Author(s)Paul C. Langley, PhD, Nicolaas Otten, PharmD, Peter Davey, MD

Download PDF: Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

over 28 years ago

Article

Coronary Heart Disease in the United States

over 28 years ago

Article

Mechanisms of Acute Coronary Events

over 28 years ago

Article

Primary Prevention

over 28 years ago

Article

Pravastatin Event Reduction Analysis

over 28 years ago

Article

Secondary Prevention

over 28 years ago

Article

Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

over 28 years ago

Article

Methods and Mindsets in Pharmacoeconomics

over 28 years ago

Article

Issues and Controversies in Pharmacoeconomics

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care